The following topics are under consideration for inclusion in IMI2 – Call 10, which is scheduled for launch in autumn 2016. The topics will also be presented, along with IMI’s rules and procedures, at the IMI Stakeholder Forum on 28-29 September in Brussels, Belgium. The event will also feature opportunities to network with fellow participants and potential applicants.
- Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
- How big data could support better diagnosis and treatment outcomes for prostate cancer
Note: topic forms part of the IMI Big Data for Better Outcomes (BD4BO) programme
- Improving the care of patients suffering from acute or chronic pain
Note: this topic consists of three subtopics:
- A : Using patient reported outcome measures to improve the management of acute and chronic pain (PROMs)
- B : Improving the translatability of pharmacodynamic biomarkers in pain pathways of healthy subjects and preclinical species (BIOM)
- C: Improving translation in chronic pelvic pain (PCC)
- Creation of a pan-European paediatric clinical trials network
- Biomanufacturing 2020: Development of innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes
- Unlocking the solute carrier gene-family for effective new therapies
- Enhanced patient voice in medicines lifecycle – feedback wanted (see below)
- Precision medicines approaches in autism spectrum disorders
Feedback on the topic on the patient voice in the medicines lifecycle
- IMI is keen to gather wider stakeholder feedback from all interested parties on the patient voice topic. If you have comments, please send them by e-mail to IMI at consultations[AT]imi.europa.eu by Wednesday 21 September. Comments received will be reviewed by staff from IMI, and shared with EFPIA representatives involved in the topic. Individual comments and details of contributors will not be made public. However, a summary of the feedback received will be published online.
All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.